Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Lennar Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Lennar Corporation trades at $83.47 (market cap $19.91B). The key difference: Lennar Corporation is far larger — about 2.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Lennar Corporation pays a 2.41% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LEN | |
|---|---|---|
Market Cap | $8.02B | $19.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $142.40 |
52-Week Low | $241.71 | $82.30 |
Enterprise Value | $7.84B | $23.79B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lennar Corporation (LEN) trades at $82.84, down 1.7% on the day, with technical indicators showing bearish momentum despite oversold RSI conditions. The stock faces fundamental pressure from declining revenue and net income margins, which fell to 6.07% in 2025 from 13.7% in 2022. Recent earnings misses and housing affordability challenges create headwinds, though analyst consensus remains positive with a $84.38 price target.
LEN presents a value opportunity with attractive valuation multiples (P/E 12.98, P/B 0.92) but faces execution risks amid declining profitability. The housing market's sensitivity to mortgage rates and competitive pressures require careful monitoring. Upside potential exists if operational improvements and housing policy support materialize, making this suitable for patient investors comfortable with cyclical exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
